Jade Biosciences, Inc. (JBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.08 Million) by net assets ($296.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Jade Biosciences, Inc. to measure how much of total assets are equity-financed.
Jade Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Jade Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Jade Biosciences, Inc. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Jade Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jade Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laurentian Bank Of Canada
TO:LB
|
0.171x |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
0.016x |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
0.003x |
|
Malaysia Building Society Bhd
KLSE:1171
|
0.025x |
|
Guizhou Broadcasting&TV Info
SHG:600996
|
0.053x |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
0.039x |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
0.047x |
|
OC Oerlikon Corp AG
SW:OERL
|
0.208x |
Annual Cash Flow Conversion Efficiency for Jade Biosciences, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Jade Biosciences, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Jade Biosciences, Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.52 Million | $-94.69 Million | -0.285x | +69.43% |
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | +94.05% |
| 2020-12-31 | $2.94 Million | $-7.86 Million | -2.672x | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more